AttendMe Owl Logo
AttendMe
Evidence Evolution
NeurologyNeurology

How This Evidence Evolved

MS Treatment Strategy

Flipping the treatment pyramid

14.4

Timeline

Signal

Early observations and pilot data that first suggested a new direction

MS disease-modifying therapies expanded after their introduction in the 1990s, creating a choice between escalation and early highly effective treatment. A review examines the benefits and risks of each strategy. Comparing individual potent drugs with moderate-efficacy agents is distinct from comparing complete treatment strategies over time.
Proof

Landmark RCTs and pivotal trials that established the evidence base

AFFIRM found that natalizumab reduced clinical relapses at 1 year by 68% versus placebo. OPERA I and II compared ocrelizumab with interferon beta-1a in relapsing multiple sclerosis. Annualized relapse rates were 0.16 versus 0.29 in each trial, corresponding to reductions of 46% and 47%, respectively. ORATORIO studied primary progressive multiple sclerosis. Disability progression confirmed at 12 weeks occurred in 32.9% with ocrelizumab versus 39.3% with placebo (HR 0.76; 95% CI 0.59–0.98). These trials established efficacy in their respective populations.
Extension

Follow-up studies, subgroup analyses, and real-world validation

In a population-based observational cohort, five-year EDSS change was 0.3 with early intensive treatment versus 1.2 with escalation (adjusted β −0.85, 95% CI −1.38 to −0.32). This association does not establish causation. A 2023 review called for randomized DELIVER-MS and TREAT-MS strategy comparisons. Ofatumumab is an anti-CD20 antibody that selectively depletes B cells; cladribine reduced relapses versus placebo over 96 weeks in relapsing-remitting MS. These individual-drug results do not settle strategy choice involving ocrelizumab.
Now

Current standard of care and ongoing research directions

The strategy question remains distinct from individual-drug efficacy. A 2023 review described support for early highly effective treatment as largely observational and called for randomized DELIVER-MS and TREAT-MS comparisons. These reports do not establish a current approved-drug count or prescribing rank. Questions include long-term safety, when treatment can stop and whether BTK inhibition can help progressive MS.

Landmark Trials in This Story

AFFIRM2006Landmark

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

Clinical relapse at 1 year: 68% reduction (P<0.001); disability progression at 2 years: 42% reduction

New England journal of medicineRCTN=942
OPERA I and II2017

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.

Annualized relapse rate over 96 weeks: ocrelizumab 0.16 vs interferon beta-1a 0.29 in both trials (46% lower in I; 47% lower in II; p<0.001 each)

The New England journal of medicineTwo phase 3 randomized controlled trials
ORATORIO2017

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.

12-week-confirmed disability progression: ocrelizumab 32.9% vs placebo 39.3% (HR 0.76, 95% CI 0.59–0.98; P=0.03)

The New England journal of medicineRandomized phase 3 trial in primary progressive multiple sclerosisN=732
Early intensive versus escalation cohort2019

Clinical Outcomes of Escalation vs Early Intensive Disease-Modifying Therapy in Patients With Multiple Sclerosis.

EDSS change at 5 years: early intensive 0.3 vs escalation 1.2 (adjusted beta -0.85; 95% CI -1.38 to -0.32; p=0.002)

JAMA neurologyPopulation-based observational cohortN=592
MS treatment-strategy evidence review2023

The benefits and risks of escalation versus early highly effective treatment in patients with multiple sclerosis.

Treatment-strategy evidence: escalation vs early highly effective therapy (narrative review)

Expert review of neurotherapeuticsNarrative review
ASCLEPIOS I and II2020

Ofatumumab versus Teriflunomide in Multiple Sclerosis.

Annualized relapse rates: ofatumumab 0.11 vs teriflunomide 0.22 (trial 1), 0.10 vs 0.25 (trial 2); serious infections 2.5% vs 1.8% (median follow-up 1.6 years).

The New England journal of medicineTwo randomized double-blind double-dummy phase 3 trials in relapsing MS
The New England journal of medicine 2010

A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.

At 96 weeks, annualized relapse rates: cumulative cladribine 3.5/5.25 mg/kg 0.14/0.15 vs placebo 0.33; lymphocytopenia 21.6%/31.5% vs 1.8%.

The New England journal of medicineRandomized placebo-controlled 96-week phase 3 trial in relapsing-remitting MSN=1,326

Explore the evidence yourself

Ask AttendMe about any trial, guideline, or clinical question. Evidence-ranked answers from 3.7M+ peer-reviewed articles.

Frequently Asked Questions

Should MS patients start with strong or mild treatment?+
The choice between escalation and early intensive therapy remains an important comparative question. In an observational cohort, 5-year EDSS change was 0.3 with early intensive treatment versus 1.2 with escalation; adjusted analyses favored early intensive treatment. This was an association from nonrandomized care. DELIVER-MS and TREAT-MS address prospective randomized comparison of these treatment strategies.
What are the most effective MS drugs available today?+
Efficacy depends on the disease form and comparator. OPERA I and II found lower annualized relapse rates with ocrelizumab than interferon beta-1a in relapsing MS: 0.16 versus 0.29 in each trial. ORATORIO found lower confirmed disability progression with ocrelizumab than placebo in primary progressive MS. Natalizumab also reduced relapse and disability-progression risks versus placebo in AFFIRM.

Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice. Clinical decisions should always be based on individual patient assessment, local guidelines, and professional judgement.

All data sourced from published, peer-reviewed articles and clinical practice guidelines.

Claims checked against cited sources: 10 November 2026